Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer

Cabazitaxel (CBZ) is approved for docetaxel‐resistant castration‐resistant prostate cancer (CRPC). However, efficacy of CBZ for CRPC is limited and there are no effective treatments for CBZ‐resistant CRPC. In order to investigate the CBZ‐resistant mechanism, the establishment of a CBZ‐resistant cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hongo, Hiroshi, Kosaka, Takeo, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125448/
https://www.ncbi.nlm.nih.gov/pubmed/29989268
http://dx.doi.org/10.1111/cas.13729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125448/
https://www.ncbi.nlm.nih.gov/pubmed/29989268
http://dx.doi.org/10.1111/cas.13729

Ejemplares similares